1,572 research outputs found
Crebiz.eu: creation of a laboratory module for teaching entrepreneurship for the media and the creative industries
O presente artigo apresenta um enquadramento das problemĂĄticas presentes no ensino universitĂĄrio de empreendedorismo no campo das indĂşstrias criativas e do jornalismo, e os resultados preliminares de uma anĂĄlise qualitativa e quantitativa acerca dos modelos atualmente em vigor a nĂvel global. Acrescenta-se como caso de estudo empĂrico as primeiras aplicaçþes prĂĄticas do projeto Crebiz.eu, nomeadamente o projeto-piloto de ensino implementado em Portugal, a sua avaliação e as reflexĂľes conclusivas sobre as prĂĄticas implementadas e as aprendizagens realizadas, na Ăłtica da continuação do projeto e da criação de um Modulo de Estudo, implementĂĄvel ao nĂvel universitĂĄrio europeu, focado numa modalidade de ensino-aprendizagem laboratorial do empreendedorismo para o jornalismo e as indĂşstrias criativas.info:eu-repo/semantics/publishedVersio
Como o jornalismo lida com a inovação: um estudo de caso das melhores pråticas em Portugal
Os meios de comunicação social estão a viver mudanças internas em consequência das
pressĂľes econĂłmicas causadas pela quebra de receitas publicitĂĄrias e/ou de audiĂŞncias. AlĂŠm das Ăłbvias contençþes de custos, que permitem adiar problemas mais profundos, hĂĄ um esforço de reformulação interna das redaçþes e dos prĂłprios produtos jornalĂsticos.
Entender como os meios de comunicação em Portugal estão a enfrentar a mudança, em
especial como estão a aplicar estratÊgias de inovação interna para inverter a diminuição de
vendas e / ou audiĂŞncias e de receitas de publicidade sĂŁo objetivos do trabalho, atravĂŠs do
qual tambĂŠm se pretende enquadrar a realidade nacional num quadro mais amplo. Mas
pretende-se tambĂŠm tentar identificar que processos estĂŁo a criar / recriar que afetam a
produção e disseminação de notĂcias, por um lado, e o fluxo de receitas, por outro, e,
portanto, que diretrizes podem ser identificadas para ajudar os legacy media ou startups
jornalĂsticas a sobreviver. Para responder Ă s questĂľes, utilizĂĄmos a observação-participante em trĂŞs redaçþes portuguesas e entrevistas semi-estruturadas aos seus responsĂĄveis editoriais. As organizaçþes foram escolhidas pela sua diversidade: uma rede de televisĂŁo que inclui um canal de sinal aberto com o noticiĂĄrio mais visto do prime time e um canal de notĂcias 24/7; uma rĂĄdio de foco noticioso e âmbito nacional; um jornal online. Observamos que tanto a TV quanto a rĂĄdio sĂŁo legacy media que, atravĂŠs de diferentes abordagens e ritmos, estĂŁo a remodelar os seus modelos de negĂłcios, processos de produção de notĂcias e produtos editoriais. O jornal nasceu como uma operação online, nĂŁo precisando de evoluir de uma lĂłgica tradicional / analĂłgica, mas tambĂŠm desenvolve estratĂŠgias de inovação.
Os resultados permitem identificar o foco dos casos estudados: as estratĂŠgias internas
nas redaçþes, as estratÊgias empreendedoras para a evolução do modelo de negócio
tradicional, e o impulsionar dos resultados financeiros.info:eu-repo/semantics/publishedVersio
Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.
BCR/ABL1-like acute lymphoblastic leukaemia (ALL) is a subgroup of B-lineage acute lymphoblastic leukaemia that occurs within cases without recurrent molecular rearrangements. Gene expression profiling (GEP) can identify these cases but it is expensive and not widely available. Using GEP, we identified 10 genes specifically overexpressed by BCR/ABL1-like ALL cases and used their expression values - assessed by quantitative real time-polymerase chain reaction (Q-RT-PCR) in 26 BCR/ABL1-like and 26 non-BCR/ABL1-like cases to build a statistical "BCR/ABL1-like predictor", for the identification of BCR/ABL1-like cases. By screening 142 B-lineage ALL patients with the "BCR/ABL1-like predictor", we identified 28/142 BCR/ABL1-like patients (19¡7%). Overall, BCR/ABL1-like cases were enriched in JAK/STAT mutations (P < 0¡001), IKZF1 deletions (P < 0¡001) and rearrangements involving cytokine receptors and tyrosine kinases (P = 0¡001), thus corroborating the validity of the prediction. Clinically, the BCR/ABL1-like cases identified by the BCR/ABL1-like predictor achieved a lower rate of complete remission (P = 0¡014) and a worse event-free survival (P = 0¡0009) compared to non-BCR/ABL1-like ALL. Consistently, primary cells from BCR/ABL1-like cases responded in vitro to ponatinib. We propose a simple tool based on Q-RT-PCR and a statistical model that is capable of easily, quickly and reliably identifying BCR/ABL1-like ALL cases at diagnosis
Estudo de PĂşblicos de Museus Nacionais - PĂşblicos do Museu Nacional de Machado de Castro
Os resultados que agora se publicam sobre os PĂşblicos do Museu Nacional de Machado de Castro (MNMC) decorrem do Estudo de PĂşblicos de Museus Nacionais (EPMN) promovido pela Direção-Geral do PatrimĂłnio Cultural (DGPC), entidade responsĂĄvel pelas polĂticas museolĂłgicas em Portugal, tendo como parceiro cientĂfico o Centro de Investigação e Estudos de Sociologia do Instituto UniversitĂĄrio de Lisboa (CIES-IUL) e o apoio mecenĂĄtico da Fundação Millennium bcp e da ONI
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma. Since its first approval 20 years ago, intravenously administered rituximab has revolutionized the treatment of B-cell malignancies and has become a standard component of care for follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma. For all of these diseases, clinical trials have demonstrated that rituximab not only prolongs the time to disease progression but also extends overall survival. Efficacy benefits have also been shown in patients with marginal zone lymphoma and in more aggressive diseases such as Burkitt lymphoma. Although the proven clinical efficacy and success of rituximab has led to the development of other anti-CD20 monoclonal antibodies in recent years (e.g., obinutuzumab, ofatumumab, veltuzumab, and ocrelizumab), rituximab is likely to maintain a position within the therapeutic armamentarium because it is well established with a long history of successful clinical use. Furthermore, a subcutaneous formulation of the drug has been approved both in the EU and in the USA for the treatment of B-cell malignancies. Using the wealth of data published on rituximab during the last two decades, we review the preclinical development of rituximab and the clinical experience gained in the treatment of hematologic B-cell malignancies, with a focus on the well-established intravenous route of administration. This article is a companion paper to A. Davies, et al., which is also published in this issue
Search for CP Violation in the Decay Z -> b (b bar) g
About three million hadronic decays of the Z collected by ALEPH in the years
1991-1994 are used to search for anomalous CP violation beyond the Standard
Model in the decay Z -> b \bar{b} g. The study is performed by analyzing
angular correlations between the two quarks and the gluon in three-jet events
and by measuring the differential two-jet rate. No signal of CP violation is
found. For the combinations of anomalous CP violating couplings, and , limits of \hat{h}_b < 0.59h^{\ast}_{b} < 3.02$ are given at 95\% CL.Comment: 8 pages, 1 postscript figure, uses here.sty, epsfig.st
Search for the glueball candidates f0(1500) and fJ(1710) in gamma gamma collisions
Data taken with the ALEPH detector at LEP1 have been used to search for gamma
gamma production of the glueball candidates f0(1500) and fJ(1710) via their
decay to pi+pi-. No signal is observed and upper limits to the product of gamma
gamma width and pi+pi- branching ratio of the f0(1500) and the fJ(1710) have
been measured to be Gamma_(gamma gamma -> f0(1500)). BR(f0(1500)->pi+pi-) <
0.31 keV and Gamma_(gamma gamma -> fJ(1710)). BR(fJ(1710)->pi+pi-) < 0.55 keV
at 95% confidence level.Comment: 10 pages, 3 figure
Search for the standard model Higgs boson in the H to ZZ to 2l 2nu channel in pp collisions at sqrt(s) = 7 TeV
A search for the standard model Higgs boson in the H to ZZ to 2l 2nu decay
channel, where l = e or mu, in pp collisions at a center-of-mass energy of 7
TeV is presented. The data were collected at the LHC, with the CMS detector,
and correspond to an integrated luminosity of 4.6 inverse femtobarns. No
significant excess is observed above the background expectation, and upper
limits are set on the Higgs boson production cross section. The presence of the
standard model Higgs boson with a mass in the 270-440 GeV range is excluded at
95% confidence level.Comment: Submitted to JHE
- âŚ